

## **CORRIGENDUM**

Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC

J. J. Knox, C. H. Barrios, T. M. Kim, T. Cosgriff, V. Srimuninnimit, K. Pittman, R. Sabbatini, S. Y. Rha, T. W. Flaig, R. D. Page, J. T. Beck, F. Cheung, S. Yadav, P. Patel, L. Geoffrois, J. Niolat, N. Berkowitz, M. Marker, D. Chen & R. J. Motzer

Ann Oncol 2017; 28: 1339–1345 (doi: 10.1093/annonc/mdx075)

In the original article, Figure 2B incorrectly described the curves as PFS, while it should have read OS. This has now been corrected.